Special Issue

Insulin Clearance and Metabolic Dysregulation in Health and Disease

Message from the Guest Editors

In the past decade, studies have highlighted the significant role of insulin clearance in obesity and the pathogenesis of Type 2 diabetes. It has been established that diminished hepatic insulin clearance results in elevated levels of insulin in the systemic circulation, consequently leading to hyperinsulinemia. Prolonged hyperinsulinemia can further impair the function of beta cells, ultimately driving the progression of Type 2 diabetes. However, the precise mechanisms that underlie the relationship between insulin clearance, metabolic dysfunction, and the pathogenesis of Type 2 diabetes remain poorly defined.

This Special Issue aims to present recent data and insights into the interplay between insulin clearance and metabolic dysfunction in health and disease. The scope of this Special Issue includes investigations in both animal models and human subjects, alongside innovative approaches such as lipidomics, metabolomics, and the discovery of biomarkers that identify changes linked to altered insulin clearance and broader metabolic pathways.

Guest Editors

Dr. Morvarid Kabir


Department of Medicine, Diabetes and Aging Center, Los Angeles, CA 90048, USA

Dr. Richard N. Bergman

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/226253

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

